Friday, November 20, 2026
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO NA Magazine > CEO Life > Health > Study: Mounjaro leads to greater weight loss than Ozempic

Study: Mounjaro leads to greater weight loss than Ozempic

in Health
Study: Mounjaro leads to greater weight loss than Ozempic
Share on LinkedinShare on WhatsApp

A major head-to-head study found that people lost significantly more weight with Eli Lilly’s diabetes drug Mounjaro compared to Novo Nordisk’s Ozempic, with similar side effects, drop-out rates, and diabetes benefits. Both drugs belong to the GLP-1 class, but Mounjaro, which contains tirzepatide, also marketed as Zepbound for weight loss, has an additional action enhancing its effectiveness. Previous studies had suggested tirzepatide led to more weight loss than semaglutide, sold as Ozempic for diabetes and Wegovy for weight loss at a higher dose.

The new study, published in JAMA Internal Medicine, analyzed data from more than 18,000 patients who started taking one of the two medications between May 2022 and September 2023, using electronic health records from Truveta, a collective of health systems with access to data on over 100 million patients. The study focused on people prescribed these drugs for type 2 diabetes, as tirzepatide was not yet approved for weight loss at the time.

By November of last year, more than half of the participants had stopped taking the medications, with 56% discontinuing tirzepatide and 53% stopping semaglutide, primarily due to gastrointestinal side effects like vomiting and nausea. The study did not indicate whether those who discontinued the drugs regained the weight they had lost.

Tags: CEOEli LillyHealthJAMA Internal MedicineNovo NordiskOzempicSemaglutideTirzepatideWeight Loss

Related Posts

U.S. Loses Measles-Free Status After 26 Years
Health

U.S. Loses Measles-Free Status After 26 Years

To be successful in 2025, a therapist says do these 5 things: It works ‘any time of year’
Health

Why switching off from work is so hard

How to Fall Asleep in 10, 60, or 120 Seconds
Health

How to Fall Asleep in 10, 60, or 120 Seconds

High Carb Foods That Are Incredibly Healthy
Health

High Carb Foods That Are Incredibly Healthy

Why ‘Binge-Watching’ That TV Show Now May Affect Your Brain Later
Health

Why ‘Binge-Watching’ That TV Show Now May Affect Your Brain Later

Get Your Vitamin P: Why Pleasure Matters When It Comes to What You Eat
Health

Get Your Vitamin P: Why Pleasure Matters When It Comes to What You Eat

Can Collagen Really Improve Your Skin Health? What the Research Says
Health

Can Collagen Really Improve Your Skin Health? What the Research Says

What Type of Procrastinator Are You?
Health

What Type of Procrastinator Are You?

Stretches to Do Before Bed
Health

Stretches to Do Before Bed

Consumers Plan to Let Restaurants Do the Cooking During the Holidays
Health

How Staying Social Can Help to Prevent Dementia

No Result
View All Result

Recent Posts

  • Why are we so obsessed with the ’90s?
  • U.S. Loses Measles-Free Status After 26 Years
  • Plane clapping – joyful or deeply cringe?
  • The 4 themes shaping new manufacturing
  • Anthropic’s total raised reaches $93.5 billion after underwriters’ greenshoe overallotment

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.